NCI Selects ATCC to Provide End-to-End Cancer Epidemiology Services
Five-year contract includes customized support for collection, tracking, storage and distribution of human biospecimens and environmental samples.
Manassas, VA, United StatesMarch 14, 2017
The National Cancer Institute (NCI) recently awarded ATCC, a global leader in biological materials development, management and standards, a five-year indefinite-delivery/indefinite-quantity (IDIQ) contract to support the Division of Cancer Epidemiology and Genetics’ (DCEG) Molecular Epidemiology Assay Support (MEAS) program.
DCEG’s mission is to conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The MEAS program provides support services for studies on the genetic and other cellular events that influence the onset of different types of cancer.
Under the contract, ATCC will provide collection supplies to study sites; perform aliquoting and advanced molecular assays; and provide short-term storage for human biospecimens and environmental samples obtained through family and population-based collection efforts, both domestically and internationally. ATCC will track all specimens using a customized biospecimen inventory and resource management system, ensuring that specimens are safeguarded appropriately for use in long-term epidemiology research projects.
“We understand that the proper collection, tracking and storage of specimens is of critical importance to cancer research, and take pride in maintaining and distributing these unique samples to the global research community,” said Dr. Joseph Leonelli, vice president for ATCC’s Microbiology and Government Solutions business. “We are excited to expand our relationship with The National Cancer Institute through this program, and look forward to expanding our clinical study capabilities to support advancements in cancer research.”
ATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cell lines and microorganisms. With a history of scientific advancements spanning nearly a century, ATCC offers an unmatched combination of being the world’s largest and most diverse collection of biological research solutions and a mission-driven, trusted partner that supports and encourages scientific collaboration. ATCC products, services and people provide the scientific community with credible biological products, advanced model systems and custom solutions that support complex research in a variety of innovative applications resulting in incredible achievements in basic science, drug discovery, translational medicine and public health. ATCC is a nonprofit organization with headquarters in Manassas, Virginia, and a research and development innovation center in Gaithersburg, Maryland.
Contact: Kim Testa, senior director, Corporate Communications & Public Affairs, ATCC, 703-365-2700 ext. 2753